Cory Hickmon joins Cancer Genetics with over twenty three years of oncology sales and sales leadership experience. His focus for the past 21 years has been the esoteric oncology testing market, with much of his career devoted to building and leading successful sales teams in the rapidly growing genetic and genomic space. Cory began his career with Impath, a recognized leader in the area of oncology and pathology esoteric testing. After several promotions, he became the Midwest Regional Manager in 1998, where he was in charge of all sales activities in one third of the US market. In this role, Cory was involved in one the earliest targeted therapy marketing campaigns in the country, the launch of Her-2/neu which qualified patients for Herceptin therapy. In 2004, Impath was acquired by Genzyme Genetics, and Cory was promoted to Southwest Regional Director based on his success at Impath. In this role, he oversaw two unique sales forces; one which was focused on oncology, the other was in the growing area of reproductive genetic and molecular testing. Again, his skills in building out sales teams were used as Genzyme went through rapid expansion during this time. In 2010, Genzyme Genetics was purchased by LabCorp. Cory graduated from the University of Houston with a B.B.A. in Finance.